GlassScriptPhysician profile
Vikas Mangewala
NPI 1750641668
$7,337.45
in general payments reported to CMS, 2019-2025
31 companies · $1,836 in 2025
The $1,836 reported for 2025 was more than what 93% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $445 · 2020: $283 · 2021: $745 · 2022: $1,188 · 2023: $1,138 · 2024: $1,703 · 2025: $1,836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,665 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,664.82 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $791.87 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $706.36 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $536.89 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $493.05 | 2020-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $479.97 | 2019-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $391.68 | 2021-2025 | Qelbree, Qelbree |
| Abbvie INC. | $386.35 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $352.77 | 2021-2022 | |
| Alkermes, INC. | $330.87 | 2019-2025 | Aristada, Lybalvi |
| Bausch Health US, LLC | $313.59 | 2019-2025 | Aplenzin |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $301.31 | 2022-2025 | Caplyta |
| Corium, LLC | $281.62 | 2022-2025 | Azstarys, Azstarys |
| Ironshore Pharmaceuticals INC. | $257.17 | 2022-2024 | Jornay Pm |
| Lundbeck LLC | $239.39 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $234.23 | 2022-2025 | Auvelity, Sunosi |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $201.42 | 2019-2025 | Trintellix |
| Tris Pharma INC | $185.97 | 2022-2025 | Dyanavel Xr |
| Allergan, INC. | $158.46 | 2019-2020 | |
| Neos Therapeutics, LP | $152.97 | 2021-2024 | Adzenys Xr-Odt |
| Collegium Pharmaceutical, INC. | $103.51 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $77.31 | 2022-2023 | Loreev Xr, Sertraline Hcl, Venlafaxine |
| Adlon Therapeutics L.P. | $67.70 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $58.18 | 2024-2025 | Cobenfy |
| Vertical Pharmaceuticals, LLC | $50.44 | 2024 | Relexxii |
| Sage Therapeutics, LLC | $42.89 | 2021-2025 | Zurzuvae |
| Indivior INC. | $41.22 | 2022-2024 | Perseris |
| Validus Pharmaceuticals LLC | $30.82 | 2022 | |
| Eisai INC. | $19.75 | 2020 | |
| Jazz Pharmaceuticals INC. | $19.73 | 2022 | |
| Brainsway USA INC | $15.24 | 2023 | |
| Avanir Pharmaceuticals, INC. | $14.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikas Mangewala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.